More on SHPGY

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (6.0 Score)
- Holders

Financials

Income Statement
Balance Sheet
Cash Flow Statement

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

SHPGY Cash Flow Statement

Click line-items for a historical chart and %
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 429.8M
Share based compensation 194.8M
Gain on sale of non-current investments
Other
Movement in deferred taxes -329.2M
Equity in earnings of equity method investees
Loss/(gain) on sale of product rights
Changes in operating assets and liabilities:
Increase in accounts receivable -181M
Increase in sales deduction accrual 66.4M
Increase in inventory -116.4M
Increase in prepayments and other assets 26.5M
Decrease in accounts payable and other liabilities 342.7M
Net cash provided by operating activities 980.4M
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash 67.2M
Purchases of subsidiary undertakings, net of cash acquired -17.48B
Purchases of non-current investments -179.1M
Purchases of property, plant and equipment ("PP&E")
Purchases of intangible assets
Proceeds from disposal of non-current investments, PP&E and product rights 0
Returns of equity investments and proceeds from short term investments
Net cash used in investing activities -17.58B
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from drawings of revolving credit facility 18.9B
Repayment of debt acquired with ABH -1.5B
Payment under building finance obligation
Extinguishment of building finance obligation
Tax benefit of stock based compensation 5.1M
Proceeds from exercise of options
Payment of dividend -130.2M
Payments to acquire shares by ESOT
Net cash used in financing activities 17.16B
Net (decrease)/increase in cash and cash equivalents 557.9M
Effect of foreign exchange rate changes on cash and cash equivalents -1.9M
Cash and cash equivalents at beginning of period 135.5M
Cash and cash equivalents at end of period 693.4M
Supplemental information associated with continuing operations:
Interest paid -111.4M
Income taxes paid -253.7M
Non cash investing and financing activities:
Equity in Vertex Pharmaceuticals, Inc. ("Vertex") received as part consideration for disposal of non-current investment